Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular disorder myasthenia gravis.

Belgian biopharma UCB has been given the green light by the FDA for Zilbrysq as a treatment for generalised myasthenia gravis (gMG), one of two drugs that the company hopes will shake up the ...

1 Department of Paediatrics, Oxford University Hospitals NHS Trust, Oxford, UK 2 Department of Paediatrics, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK ...

Thymidine kinase 2 deficiency (TK2d) affects many organs and systems, leading to a variety of clinical features. However, the main clinical features of TK2d are progressive muscle weakness, dysphagia, ...

Graviss Hospitality Ltd., incorporated in the year 1959, is a Small Cap company (having a market cap of Rs 286.31 Crore) operating in Tourism & Hospitality sector. Graviss Hospitality Ltd. key ...